Similar Papers

Paper Title
Journal
Date
Author
Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Nitin Jain ...
Blood | VOL. 138
Nitin Jain, et. al.Nitin Jain ...
05 Nov 2021
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results
Nitin Jain ...
Blood | VOL. 138
Nitin Jain, et. al.Nitin Jain ...
05 Nov 2021
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Hanna Weissbrot ...
Blood | VOL. 134
Hanna Weissbrot, et. al.Hanna Weissbrot ...
13 Nov 2019
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Naval Daver ...
Blood | VOL. 138
Naval Daver, et. al.Naval Daver ...
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements
Qiudan Shen ... Shimin Hu
Blood | VOL. 145
Qiudan Shen, et. al.Qiudan Shen ... Shimin Hu
06 Feb 2025
The dark zone of CNS relapse in DLBCL
Kieron Dunleavy
Blood | VOL. 145
Kieron DunleavyKieron Dunleavy
06 Feb 2025
Impact of new medications on the treatment of Immune TTP.
Marie Scully ... William A Lester
Blood | VOL. -
Marie Scully, et. al.Marie Scully ... William A Lester
06 Feb 2025
No exit: targeting RNA export in T-cell malignancy
Katherine L B Borden
Blood | VOL. 145
Katherine L B BordenKatherine L B Borden
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.